sales@businessmarketinsights.com +1 646 791 7070 | +91-020 69018608

Cancer Hormone Therapy Market Size & Forecast

Download Free Sample View Report Summary
Historic: 2021-2023 Base Year: 2024 Forecast: 2025–2031
US$ 26.61 Billion
Market Size 2024 · Base Year
US$ 58.58 Billion
Projected Market Size by 2031
11.93%
CAGR · 2025–2031
Download Free Sample View Report Summary
sales@businessmarketinsights.com +1 646 791 7070 | +91-020 69018608
SHARE
BMIPUB00031708 56+ Countries Covered 10 Major Companies Profiled PEST & SWOT Analysis Competitive Heat Map
At a Glance

Report Coverage

56 +
Countries
56+ countries across North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa
11
Year Assessment
Comprehensive Market Analysis Covering 3 Years of Historical Data (2021–2023), Base Year (2024), and 7-Year Forecast (2025–2031)
10 +
Major Players
Major companies profiled including Astellas Pharma Inc, Eli Lilly and Co, Novartis AG, Merck KGaA, Johnson & Johnson
200
Report Pages
Pages of deep-dive analysis with PEST, SWOT, competitive heat maps and datasets
What's Fueling Growth

Market Drivers

  • Rising Incidence of Hormone-Responsive Cancers

  • Advancements in Targeted Hormone Therapies

Where Growth Opportunities Exist

Key Opportunities

  • Development of Personalized Hormone Therapy Regimens

  • Expansion of Oral Hormone Therapy Pipeline

What Could Slow It Down

Market Restraints

  • Limited efficacy in some cancer

  • Side effect

  • High cost burden

Market Segmentation

Coverage by Segment

Drug Class

GnRH Analogs
GnRH Antagonists
Androgen Receptor Antagonists

Cancer Type

Breast Cancer
Prostate Cancer
Endometrial Cancer

Route of Administration

Oral
Injectable
Implantable

Sales Channel

Hospitals
Specialty Clinics
Cancer Treatment Centers
Geographic Breakdown

Regional Intelligence

NA North America
EU Europe
APAC Asia-Pacific
SCA South & Central America
MEA Middle East & Africa
Competitive Landscape

Major Market Players

Listed for reference — companies are not ranked in any particular order.

Astellas Pharma Inc
Eli Lilly and Co
Novartis AG
Merck KGaA
Johnson & Johnson
AstraZeneca
Pfizer Inc
Bristol Myers Squibb
F. Hoffmann-La Roche Ltd
AbbVie
What's Inside

Report Scope & Deliverables

Market Size 2024 US$ 26.61 Billion
Market Size 2031 US$ 58.58 Billion
CAGR 2025–2031 11.93%
Segments By Drug Class (GnRH Analogs, GnRH Antagonists, Androgen Receptor Antagonists)  |  By Cancer Type (Breast Cancer, Prostate Cancer, Endometrial Cancer)  |  By Route of Administration (Oral, Injectable, Implantable)
Geographies North America (US, Canada, Mexico)  ·  Europe (Germany, Italy, France, U.K., Spain, Belgium, Netherlands, Luxembourg, Norway, Finland, Denmark, Sweden, Switzerland, Austria, Greece, Portugal, Russia, Poland, Romania, Czech Republic, Ukraine, Slovakia, Bulgaria)  ·  Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Taiwan, Bangladesh)  ·  South and Central America (Brazil, Argentina, Chile, Colombia, Peru)  ·  Middle East and Africa (Saudi Arabia, United Arab Emirates, Kuwait, Bahrain, Qatar, Oman, Turkiye, South Africa, Egypt, Nigeria, Algeria)
Deliverables Historical analysis with CAGR · PEST & SWOT analysis · Market Size at Global, Regional, and Country Levels · Competitive heat map · Company profiles · Excel dataset
Report Code BMIPUB00031708
Lead Analyst Krishna Sunthwal — Analyst, Research · View Profile
With Full Report Access

Gain actionable insights with 200 pages of in-depth Cancer Hormone Therapy Market, including historical trends, 7-year market forecasts, SWOT analysis, competitive landscapes, and downloadable Excel datasets in a single comprehensive package.

View Report Summary Download Free Sample